Platelet Transfusions in Critically Ill Patient

NCT ID: NCT03325140

Last Updated: 2019-07-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-30

Study Completion Date

2019-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Between 10 and 15% of critically ill patients require platelet transfusion within their intensive care unit (ICU).

Platelets (PLT) are given to prevent bleeding in thrombocytopenic patients or to treat bleeding as part of massive transfusion or in bleeding thrombocytopenic patients.

International and local guidelines (American Association of Blood Banks-AABB) are mainly based on experts' opinion. The efficacy of PLT transfusion in the ICU setting remains poorly studied and unknown and the administration of PLT may be associated with adverse effects including an increased risk of hospital acquired infection. Finally, the short PLT shelve-life may be responsible for inventory issues. Altogether, this makes very important to improve the evidence that support PLT transfusion in ICU patients.

This is a multicentre prospective observational study that aims to first determine PLT transfusion efficacy and to identify the parameters associated with transfusion efficacy and to analyse the compliance with international (and local) guidelines of PLT transfusion in ICU patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Transfusion Critical Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted to intensive care and receiving at least one platelet transfusion in intensive care unit

Exclusion Criteria

* Age less than 18
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Brest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU d'Angers

Angers, , France

Site Status RECRUITING

CHRU de Brest

Brest, , France

Site Status RECRUITING

CH des Pays de Morlaix

Morlaix, , France

Site Status RECRUITING

CHU de Nantes

Nantes, , France

Site Status RECRUITING

CHU de Rennes

Rennes, , France

Site Status RECRUITING

CHU de Tours

Tours, , France

Site Status RECRUITING

Chba Site de Vannes

Vannes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

AUBRON Cécile

Role: CONTACT

+33 2 98 34 78 59

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pierre ASFAR, Pr

Role: primary

Aubron Cécile

Role: primary

Pierre-Yves EGRETEAU

Role: primary

02 98 62 61 60

LE MEUR Anthony

Role: primary

SEGUIN Philippe

Role: primary

EHRMANN Stephan

Role: primary

Julien HUNTZINGER

Role: primary

06-33-58-02-04

References

Explore related publications, articles, or registry entries linked to this study.

Reizine F, Le Marec S, Le Meur A, Consigny M, Berteau F, Bodenes L, Geslain M, McQuilten Z, Le Niger C, Huntzinger J, Seguin P, Thibert JB, Simon D, Reignier J, Egreteau PY, Tadie JM, Huet O, Asfar P, Ehrmann S, Aubron C. Prophylactic platelet transfusion response in critically ill patients: a prospective multicentre observational study. Crit Care. 2023 Sep 27;27(1):373. doi: 10.1186/s13054-023-04650-z.

Reference Type DERIVED
PMID: 37759268 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RE-CCIP (29BRC17.0157)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transfusion in Gastrointestinal Bleeding
NCT02105532 COMPLETED PHASE2/PHASE3